Ocular Therapeutix (OCUL) Retained Earnings (2013 - 2026)
Ocular Therapeutix (OCUL) posted quarterly Retained Earnings of -$1.3 billion for Q2 2026, down 29.47% year-over-year from -$1.9 billion in Q2 2025, and down 6.32% on a QoQ basis from -$1.2 billion in Q1 2026.
Ocular Therapeutix (OCUL) Retained Earnings (2013 - 2026) Analysis & Trends
Ocular Therapeutix has reported Retained Earnings for 14 years, with the latest figure at -$1.3 billion in Q2 2026.
- Retained Earnings for Q2 2026 came in at -$1.3 billion, down 29.47% year-over-year; the trailing twelve-month figure through Jun 2026 was -$1.3 billion (down 29.47% YoY), and the FY2025 annual result was -$1.2 billion, down 29.84% from the prior year.
- Retained Earnings declined to -$1.3 billion in Q2 2026, from -$1.2 billion in the prior quarter.
- Over five years, Retained Earnings peaked at -$558.3 million in Q1 2022 and troughed at -$1.3 billion in Q2 2026.
- A 5-year average of -$840.8 million and a median of -$784.3 million in 2024 frame the typical range for Retained Earnings.
- The widest annual swing landed in 2022, when Retained Earnings decreased 4.14%; it then sank 30.41% in 2026.
- A 5-year view of Retained Earnings shows it stood at -$616.8 million in 2022, then fell by 13.09% to -$697.6 million in 2023, then fell by 27.74% to -$891.1 million in 2024, then retreated by 29.84% to -$1.2 billion in 2025, then decreased by 14.47% to -$1.3 billion in 2026.
- Per Business Quant data, the three most recent Retained Earnings figures were -$1.3 billion in Q2 2026, -$1.2 billion in Q1 2026, and -$1.2 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Ocular Therapeutix | 2.20 Bn | 2.20 Bn | 11.46 Mn | -1.32 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.32 Bn |
| Mar 31, 2026 | -1.25 Bn |
| Dec 31, 2025 | -1.16 Bn |
| Sep 30, 2025 | -1.09 Bn |
| Jun 30, 2025 | -1.02 Bn |
| Mar 31, 2025 | -955.14 Mn |
| Dec 31, 2024 | -891.08 Mn |
| Sep 30, 2024 | -842.70 Mn |
| Jun 30, 2024 | -806.20 Mn |
| Mar 31, 2024 | -762.43 Mn |
| Dec 31, 2023 | -697.58 Mn |
| Sep 30, 2023 | -668.36 Mn |
| Jun 30, 2023 | -667.84 Mn |
| Mar 31, 2023 | -647.16 Mn |
| Dec 31, 2022 | -616.84 Mn |
| Sep 30, 2022 | -601.30 Mn |
| Jun 30, 2022 | -577.11 Mn |
| Mar 31, 2022 | -558.35 Mn |
| Dec 31, 2021 | -545.80 Mn |
| Sep 30, 2021 | -541.95 Mn |